查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1822373

2032 年治療性神經毒素市場預測：按產品類型、配方、給藥途徑、技術、治療用途、最終用戶和地區進行的全球分析

Therapeutic Neurotoxin Market Forecasts to 2032 - Global Analysis By Product Type (Botulinum Toxin Type A and Botulinum Toxin Type B), Formulation, Administration Route, Technology, Therapeutic Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球治療性神經毒素市場預計在 2025 年達到 64.7 億美元，預計到 2032 年將達到 130.2 億美元，預測期內的複合年成長率為 10.5%。

治療性神經毒素，主要是肉毒桿菌毒素，是經過基因工程改造用於醫療用途的生技藥品。肉毒桿菌毒素透過阻斷特定肌肉的神經傳導，從而控制肌肉放鬆並抑制過度活動。這些藥物通常用於治療偏頭痛、肌張力不全症、痙攣和膀胱功能障礙等疾病。作為一種非手術治療方法，神經毒素療法已被證明安全有效。正在進行的研究正在進一步拓展神經毒素在治療複雜神經和肌肉疾病方面的作用。

神經肌肉疾病盛行率上升

痙攣、慢性偏頭痛和肌張力不全症等神經系統疾病的盛行率不斷上升，推動了對治療性神經毒素的需求。人口老化和診斷能力的提高，使得已開發經濟體和新興經濟體的患者群體不斷擴大。肉毒桿菌等神經毒素正被納入個人化治療通訊協定，以更有效地管理肌肉功能障礙。醫院和專科診所正在將這些治療方法作為外科手術的非侵入性替代方案。標靶給藥和緩釋性製劑的創新正在改善治療方法效果。隨著認知度的提高，神經毒素正成為神經病學和復健多學科治療的核心。

嚴格的監管核准流程

治療性神經毒素因其強大的生物活性和複雜的生產要求而面臨嚴格的監管審查。核准流程通常漫長，需要大量的臨床試驗和安全檢驗。 FDA 和 EMA 等監管機構要求提供嚴格的文件記錄，尤其是針對新適應症和配方變更。先進的給藥系統和數位監控工具的整合增加了合規性的複雜性。規模較小的生技公司往往難以應對監管成本和專家指導管道的有限性，減緩了創新。這些挑戰可能會延遲產品上市，並限制某些地區的市場擴張。

神經毒素製劑的進展

研究人員正在開發長效且溫度穩定的製劑，以提高患者用藥便利性並減少給藥頻率。封裝和標靶給藥方面的創新正在提高精準度並最大限度地減少副作用。新興趨勢包括將神經毒素與佐劑結合以產生協同作用的混合製劑。監管機構擴大接受安全性和有效性更高的新型製劑。這些進展為擴大其在各種醫療環境中的適應症鋪平了道路，包括疼痛管理和膀胱功能障礙。

替代治療方法的可用性

副作用較少的非侵入性治療正日益受到患者和醫療保健提供者的青睞。針對類似途徑的生物製藥和基因療法正成為潛在的替代方案。此外，考慮到成本和報銷限制，偏好可能會轉向更經濟實惠的治療方案。神經調節和穿戴式裝置的技術進步為肌肉疾病的治療開闢了新的途徑。如果沒有持續的創新和臨床檢驗，神經毒素可能會被這些不斷發展的替代方案所掩蓋。

COVID-19的影響

疫情擾亂了神經毒素供應鏈，推遲了擇期手術，並影響了市場發展動能。封鎖和重症加護監護資源的重新分配減少了患者獲得治療性注射的機會。然而，這場危機加速了數位醫療的普及，包括針對慢性神經系統疾病的遠距會診和遠端患者監護。疫情後的復甦以重新關注分散式照護和門診治療模式為標誌。市場目前正在轉向韌性、自動化和靈活的分銷策略，以緩解未來的市場波動。

液體製劑市場預計將成為預測期內最大的市場

液體製劑因其易於給藥且起效迅速，預計將在預測期內佔據最大的市場佔有率。由於劑量穩定且製備要求低，這些製劑在臨床環境中更受青睞。穩定性和保存期限的技術改進正在提升其在全部區域的吸引力。液體神經毒素擴大用於門診治療，這與微創治療的趨勢相符。製造商正在投資包裝創新，以支持低溫運輸物流並減少浪費。在對高效且可擴展解決方案的需求日益成長的背景下，液體製劑在治療應用方面繼續引領潮流。

預計專科診所部門在預測期內的複合年成長率最高。

在集中式專業知識和以患者為中心的護理模式的推動下，專科診所預計將在預測期內實現最高成長率。這些機構正迅速採用神經毒素治療頸部肌張力不全症和眼瞼痙攣等疾病。先進的影像學和肌電圖引導注射技術的整合正在提高治療精準度。診所受益於簡化的工作流程和更快的患者周轉時間，從而提高了營運效率。新興趨勢包括行動神經毒素單元和數位化調度平台，以擴大可及性。隨著醫療保健日益分散化，專科診所在提供有針對性的神經毒素治療方面變得至關重要。

比最大的地區

由於醫療保健投資不斷增加以及神經系統疾病負擔日益加重，預計亞太地區將在預測期內佔據最大市場佔有率。中國、印度和韓國等國家正在透過公共衛生措施和不斷發展的私營部門擴大神經毒素治療的可及性。本地生產和有利的監管改革正在提高產品的可及性和可負擔性。該地區肉毒桿菌毒素在治療和美容領域的應用日益廣泛。跨國公司與本地經銷商之間的策略聯盟正在加速市場滲透。

複合年成長率最高的地區：

在預測期內，北美預計將呈現最高的複合年成長率，這得益於其強大的開發平臺和創新神經毒素治療方法的早期應用。美國和加拿大在探索擴大適應症和新型給藥系統的臨床試驗方面處於領先地位。監管機構正在簡化下一代製劑的核准流程，以促進更快的商業化。醫院和專科診所正在整合基於人工智慧的診斷和與電子病歷 (EMR) 相關的治療通訊協定，以最佳化神經毒素的使用。保險報銷框架和醫生培訓計劃正在推動神經毒素的廣泛應用。

提供免費客製化：

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球治療性神經毒素市場（依產品類型）

  • A型肉毒桿菌毒素
    • 肉毒桿菌
    • 傑沃
    • Dysport
    • Xeomin
  • B型肉毒桿菌
    • 肌阻斷劑

6. 全球治療性神經毒素市場（按配方）

  • 液體製劑
  • 凍乾粉
  • 劑量強度
  • 組合產品和組合藥物

7. 全球治療性神經毒素市場（依給藥途徑）

  • 肌肉注射
  • 腺內注射
  • 皮內注射
  • 新型藥物傳輸平台

8. 全球治療性神經毒素市場（按技術）

  • 純化的天然毒素
  • 人工神經毒素
  • 配方技術
  • 契約製造和CDMO

9. 全球治療性神經毒素市場（依治療應用）

  • 慢性偏頭痛
  • 眼瞼痙攣
  • 痙攣
  • 多汗症
  • 頸部肌張力不全症
  • 膀胱過動症
  • 顳顎關節障礙症

10. 全球治療性神經毒素市場（依最終用戶）

  • 醫院
  • 專科診所
  • 復健設施
  • 神經內科中心
  • 其他最終用戶

11. 全球治療性神經毒素市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章：企業概況

  • AbbVie Inc.
  • Lanzhou Institute of Biological Products Co., Ltd.
  • Ipsen Pharma
  • Shanghai Haohai Biological Technology Co., Ltd.
  • Revance Therapeutics, Inc.
  • Croma-Pharma GmbH
  • Medytox, Inc.
  • Allergan Aesthetics
  • Hugel, Inc.
  • Toxogen Ltd.
  • Daewoong Pharmaceutical Co., Ltd.
  • Sino Biopharmaceutical Limited
  • Evolus, Inc.
  • US WorldMeds, LLC
  • Merz Pharmaceuticals GmbH
Product Code: SMRC31127

According to Stratistics MRC, the Global Therapeutic Neurotoxin Market is accounted for $6.47 billion in 2025 and is expected to reach $13.02 billion by 2032 growing at a CAGR of 10.5% during the forecast period. Therapeutic neurotoxins, mainly based on botulinum toxin, are biological agents designed for medical use. They act by interrupting nerve communication with specific muscles, leading to controlled relaxation and reduced over activity. These agents are commonly prescribed for disorders like migraines, dystonia, spasticity, and bladder dysfunction. Offering a non-surgical treatment approach, therapeutic neurotoxins ensure safety and effectiveness. Ongoing studies are further broadening their role in addressing complex neurological and muscular health conditions.

Market Dynamics:

Driver:

Rising prevalence of neurological and muscular disorders

The increasing incidence of neurological conditions such as spasticity, chronic migraines, and dystonia is fuelling demand for therapeutic neurotoxins. Aging populations and improved diagnostic capabilities are expanding the patient pool across both developed and emerging economies. Neurotoxins like botulinum toxin are being integrated into personalized treatment protocols to manage muscular dysfunctions more effectively. Hospitals and specialty clinics are adopting these therapies as non-invasive alternatives to surgical interventions. Technological innovations in targeted delivery and sustained-release formulations are enhancing therapeutic outcomes. As awareness grows, neurotoxins are becoming central to multidisciplinary approaches in neurology and rehabilitation.

Restraint:

Strict regulatory approval processes

Therapeutic neurotoxins face stringent regulatory scrutiny due to their potent biological activity and complex manufacturing requirements. Approval pathways are often prolonged, requiring extensive clinical trials and safety validations. Regulatory bodies such as the FDA and EMA demand rigorous documentation, especially for new indications and formulation changes. The integration of advanced delivery systems and digital monitoring tools adds layers of complexity to compliance. Smaller biotech firms often struggle with regulatory costs and limited access to expert guidance, slowing innovation. These challenges can delay product launches and restrict market expansion in certain regions.

Opportunity:

Advancements in neurotoxin formulations

Researchers are developing long-acting variants and temperature-stable formulations to improve patient convenience and reduce dosing frequency. Innovations in encapsulation and targeted delivery are enhancing precision and minimizing side effects. Emerging trends include hybrid formulations combining neurotoxins with adjunctive agents for synergistic effects. Regulatory agencies are increasingly receptive to novel formulations that demonstrate improved safety and efficacy. These advancements are opening doors for expanded indications, including pain management and bladder dysfunction, across diverse healthcare settings.

Threat:

Availability of alternative treatment options

Non-invasive treatments with fewer side effects are gaining traction among patients and providers. Biologics and gene therapies targeting similar pathways are emerging as potential substitutes. Cost considerations and reimbursement limitations may also shift preference toward more affordable options. Technological progress in neuromodulation and wearable devices is offering new avenues for managing muscular disorders. Without continuous innovation and clinical validation, neurotoxins risk losing ground to these evolving alternatives.

Covid-19 Impact

The pandemic disrupted neurotoxin supply chains and delayed elective procedures, impacting market momentum. Lockdowns and resource reallocation toward critical care reduced patient access to therapeutic injections. However, the crisis accelerated digital health adoption, including teleconsultations and remote patient monitoring for chronic neurological conditions. Post-pandemic recovery is marked by renewed focus on decentralized care and outpatient treatment models. The market is now pivoting toward resilience, automation, and flexible distribution strategies to mitigate future disruptions.

The liquid formulations segment is expected to be the largest during the forecast period

The liquid formulations segment is expected to account for the largest market share during the forecast period, due to its ease of administration and rapid onset of action. These formulations are preferred in clinical settings for their consistent dosing and minimal preparation requirements. Technological improvements in stability and shelf-life are enhancing their appeal across geographies. Liquid neurotoxins are increasingly used in outpatient procedures, aligning with trends in minimally invasive care. Manufacturers are investing in packaging innovations to support cold-chain logistics and reduce wastage. As demand rises for efficient and scalable solutions, liquid formulations continue to lead in therapeutic adoption.

The specialty clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the specialty clinics segment is predicted to witness the highest growth rate, driven by their focused expertise and patient-centric care models. These facilities are rapidly adopting neurotoxin therapies for conditions like cervical dystonia and blepharospasm. Integration of advanced imaging and EMG-guided injection techniques is improving treatment precision. Clinics benefit from streamlined workflows and shorter patient turnaround times, enhancing operational efficiency. Emerging trends include mobile neurotoxin units and digital scheduling platforms to expand access. As healthcare decentralizes, specialty clinics are becoming pivotal in delivering targeted neurotoxin interventions.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share supported by rising healthcare investments and growing neurological disease burden. Countries like China, India, and South Korea are expanding access to neurotoxin therapies through public health initiatives and private sector growth. Local manufacturing and favorable regulatory reforms are boosting product availability and affordability. The region is witnessing increased adoption of botulinum toxin for both therapeutic and aesthetic applications. Strategic collaborations between global players and regional distributors are accelerating market penetration.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by strong R&D pipelines and early adoption of innovative neurotoxin therapies. The U.S. and Canada are at the forefront of clinical trials exploring expanded indications and novel delivery systems. Regulatory agencies are streamlining approval processes for next-gen formulations, encouraging rapid commercialization. Hospitals and specialty clinics are integrating AI-based diagnostics and EMR-linked treatment protocols to optimize neurotoxin use. Reimbursement frameworks and physician training programs are supporting widespread adoption.

Key players in the market

Some of the key players profiled in the Therapeutic Neurotoxin Market include AbbVie Inc., Lanzhou Institute of Biological Products Co., Ltd., Ipsen Pharma, Shanghai Haohai Biological Technology Co., Ltd., Revance Therapeutics, Inc., Croma-Pharma GmbH, Medytox, Inc., Allergan Aesthetics, Hugel, Inc., Toxogen Ltd., Daewoong Pharmaceutical Co., Ltd., Sino Biopharmaceutical Limited, Evolus, Inc., US WorldMeds, LLC, and Merz Pharmaceuticals GmbH.

Key Developments:

In August 2025, AbbVie and Gilgamesh Pharmaceuticals Inc. announced a definitive agreement under which AbbVie will acquire Gilgamesh's lead investigational candidate, currently in clinical development for the treatment of patients with moderate-to-severe major depressive disorder (MDD).

In February 2021, Haohai Biological Technology announced that it acquired 63.64% shares in JUVA (Tianjin) Medical Technology Co., Ltd with a total investment of RMB 205 million Yuan, including JUVA's EndyMed RF skin equipment and instruments, Lasercon's VCSEL laser chips and equipment and Bioxis tissue filler and other main businesses and products into its medical aesthetics business portfolio.

Product Types Covered:

  • Botulinum Toxin Type A
  • Botulinum Toxin Type B

Formulations Covered:

  • Liquid Formulations
  • Lyophilized Powders
  • Dosage Strengths
  • Combination Products & Co-formulations

Administration Routes Covered:

  • Intramuscular Injection
  • Intraglandular Injection
  • Intradermal Injection
  • Novel Delivery Platforms

Technologies Covered:

  • Purified Native Toxins
  • Engineered Neurotoxins
  • Formulation Technologies
  • Contract Manufacturing & CDMOs

Therapeutic Applications Covered:

  • Chronic Migraine
  • Blepharospasm
  • Spasticity
  • Hyperhidrosis
  • Cervical Dystonia
  • Overactive Bladder
  • Temporomandibular Disorders

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Rehabilitation Facilities
  • Neurology Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Therapeutic Neurotoxin Market, By Product Type

  • 5.1 Introduction
  • 5.2 Botulinum Toxin Type A
    • 5.2.1 Botox
    • 5.2.2 Jeuveau
    • 5.2.3 Dysport
    • 5.2.4 Xeomin
  • 5.3 Botulinum Toxin Type B
    • 5.3.1 Myobloc

6 Global Therapeutic Neurotoxin Market, By Formulation

  • 6.1 Introduction
  • 6.2 Liquid Formulations
  • 6.3 Lyophilized Powders
  • 6.4 Dosage Strengths
  • 6.5 Combination Products & Co-formulations

7 Global Therapeutic Neurotoxin Market, By Administration Route

  • 7.1 Introduction
  • 7.2 Intramuscular Injection
  • 7.3 Intraglandular Injection
  • 7.4 Intradermal Injection
  • 7.5 Novel Delivery Platforms

8 Global Therapeutic Neurotoxin Market, By Technology

  • 8.1 Introduction
  • 8.2 Purified Native Toxins
  • 8.3 Engineered Neurotoxins
  • 8.4 Formulation Technologies
  • 8.5 Contract Manufacturing & CDMOs

9 Global Therapeutic Neurotoxin Market, By Therapeutic Application

  • 9.1 Introduction
  • 9.2 Chronic Migraine
  • 9.3 Blepharospasm
  • 9.4 Spasticity
  • 9.5 Hyperhidrosis
  • 9.6 Cervical Dystonia
  • 9.7 Overactive Bladder
  • 9.8 Temporomandibular Disorders

10 Global Therapeutic Neurotoxin Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Specialty Clinics
  • 10.4 Rehabilitation Facilities
  • 10.5 Neurology Centers
  • 10.6 Other End Users

11 Global Therapeutic Neurotoxin Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 AbbVie Inc.
  • 13.2 Lanzhou Institute of Biological Products Co., Ltd.
  • 13.3 Ipsen Pharma
  • 13.4 Shanghai Haohai Biological Technology Co., Ltd.
  • 13.5 Revance Therapeutics, Inc.
  • 13.6 Croma-Pharma GmbH
  • 13.7 Medytox, Inc.
  • 13.8 Allergan Aesthetics
  • 13.9 Hugel, Inc.
  • 13.10 Toxogen Ltd.
  • 13.11 Daewoong Pharmaceutical Co., Ltd.
  • 13.12 Sino Biopharmaceutical Limited
  • 13.13 Evolus, Inc.
  • 13.14 US WorldMeds, LLC
  • 13.15 Merz Pharmaceuticals GmbH

List of Tables

  • Table 1 Global Therapeutic Neurotoxin Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Therapeutic Neurotoxin Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Therapeutic Neurotoxin Market Outlook, By Botulinum Toxin Type A (2024-2032) ($MN)
  • Table 4 Global Therapeutic Neurotoxin Market Outlook, By Botox (2024-2032) ($MN)
  • Table 5 Global Therapeutic Neurotoxin Market Outlook, By Jeuveau (2024-2032) ($MN)
  • Table 6 Global Therapeutic Neurotoxin Market Outlook, By Dysport (2024-2032) ($MN)
  • Table 7 Global Therapeutic Neurotoxin Market Outlook, By Xeomin (2024-2032) ($MN)
  • Table 8 Global Therapeutic Neurotoxin Market Outlook, By Botulinum Toxin Type B (2024-2032) ($MN)
  • Table 9 Global Therapeutic Neurotoxin Market Outlook, By Myobloc (2024-2032) ($MN)
  • Table 10 Global Therapeutic Neurotoxin Market Outlook, By Formulation (2024-2032) ($MN)
  • Table 11 Global Therapeutic Neurotoxin Market Outlook, By Liquid Formulations (2024-2032) ($MN)
  • Table 12 Global Therapeutic Neurotoxin Market Outlook, By Lyophilized Powders (2024-2032) ($MN)
  • Table 13 Global Therapeutic Neurotoxin Market Outlook, By Dosage Strengths (2024-2032) ($MN)
  • Table 14 Global Therapeutic Neurotoxin Market Outlook, By Combination Products & Co-formulations (2024-2032) ($MN)
  • Table 15 Global Therapeutic Neurotoxin Market Outlook, By Administration Route (2024-2032) ($MN)
  • Table 16 Global Therapeutic Neurotoxin Market Outlook, By Intramuscular Injection (2024-2032) ($MN)
  • Table 17 Global Therapeutic Neurotoxin Market Outlook, By Intraglandular Injection (2024-2032) ($MN)
  • Table 18 Global Therapeutic Neurotoxin Market Outlook, By Intradermal Injection (2024-2032) ($MN)
  • Table 19 Global Therapeutic Neurotoxin Market Outlook, By Novel Delivery Platforms (2024-2032) ($MN)
  • Table 20 Global Therapeutic Neurotoxin Market Outlook, By Technology (2024-2032) ($MN)
  • Table 21 Global Therapeutic Neurotoxin Market Outlook, By Purified Native Toxins (2024-2032) ($MN)
  • Table 22 Global Therapeutic Neurotoxin Market Outlook, By Engineered Neurotoxins (2024-2032) ($MN)
  • Table 23 Global Therapeutic Neurotoxin Market Outlook, By Formulation Technologies (2024-2032) ($MN)
  • Table 24 Global Therapeutic Neurotoxin Market Outlook, By Contract Manufacturing & CDMOs (2024-2032) ($MN)
  • Table 25 Global Therapeutic Neurotoxin Market Outlook, By Therapeutic Application (2024-2032) ($MN)
  • Table 26 Global Therapeutic Neurotoxin Market Outlook, By Chronic Migraine (2024-2032) ($MN)
  • Table 27 Global Therapeutic Neurotoxin Market Outlook, By Blepharospasm (2024-2032) ($MN)
  • Table 28 Global Therapeutic Neurotoxin Market Outlook, By Spasticity (2024-2032) ($MN)
  • Table 29 Global Therapeutic Neurotoxin Market Outlook, By Hyperhidrosis (2024-2032) ($MN)
  • Table 30 Global Therapeutic Neurotoxin Market Outlook, By Cervical Dystonia (2024-2032) ($MN)
  • Table 31 Global Therapeutic Neurotoxin Market Outlook, By Overactive Bladder (2024-2032) ($MN)
  • Table 32 Global Therapeutic Neurotoxin Market Outlook, By Temporomandibular Disorders (2024-2032) ($MN)
  • Table 33 Global Therapeutic Neurotoxin Market Outlook, By End User (2024-2032) ($MN)
  • Table 34 Global Therapeutic Neurotoxin Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 35 Global Therapeutic Neurotoxin Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 36 Global Therapeutic Neurotoxin Market Outlook, By Rehabilitation Facilities (2024-2032) ($MN)
  • Table 37 Global Therapeutic Neurotoxin Market Outlook, By Neurology Centers (2024-2032) ($MN)
  • Table 38 Global Therapeutic Neurotoxin Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.